Property update — November–December 2013: Community Infrastructure Levy
A draft of the latest set of amendments to the CIL Regulations 2010 has been laid before Parliament. Here is a list a few of the proposed changes.
Part 11 of the Planning Act 2008 provided for the imposition of a charge known as the Community Infrastructure Levy (CIL). The CIL Regulations 2010 implemented the detail of the levy, and local authorities have been able (but not obliged) to impose CIL on certain developments in England and Wales since April 2010.
A draft of the proposed CIL (Amendments) Regulations 2014 has been laid before Parliament. They will come into force the day after they are finalised and made — most likely in January 2014. This is the fourth set of amendments to the 2010 regulations…
If you are registered and logged in to the site, click on the link below to read the rest of the Wragge & Co briefing. If not, please register or sign in with your details below.
Sign in or Register to continue reading this article
It's quick, easy and free!
It takes just 5 minutes to register. Answer a few simple questions and once completed you’ll have instant access.Register now
Why register to The Lawyer
In-depth, expert analysis into the stories behind the headlines from our leading team of journalists.
Identify the major players and business opportunities within a particular region through our series of free, special reports.
Receive your pick of The Lawyer's daily and weekly email newsletters, tailored by practice area, region and job function.
More relevant to you
To continue providing the best analysis, insight and news across the legal market we are collecting some information about who you are, what you do and where you work to improve The Lawyer and make it more relevant to you.
News from Wragge Lawrence Graham & Co
News from The Lawyer
Briefings from Wragge Lawrence Graham & Co
Ruling on an application for specific disclosure could have big implications in the early stages of procurement disputes.
Hospira v Genentech III: Swiss form claim obvious in view of paper reporting the existence of Phase III trial
Arnold J has delivered the latest blow in the ongoing saga surrounding trastuzumab (the monoclonal antibody in Herceptin) and Hospira’s continued efforts to knock out Genentech’s patents.